Natera (NASDAQ:NTRA) Insider John Fesko Sells 339 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 339 shares of Natera stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $79,665.00. Following the completion of the sale, the insider directly owned 177,252 shares in the company, valued at approximately $41,654,220. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

John Fesko also recently made the following trade(s):

• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $4,179,780.44.
• On Tuesday, October 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $177,674.88.
• On Monday, October 27th, John Fesko sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $150,201.92.

Natera Trading Up 0.1%

Shares of NASDAQ:NTRA traded up $0.13 during trading on Thursday, reaching $242.91. The company’s stock had a trading volume of 971,052 shares, compared to its average volume of 950,311. The stock has a market capitalization of $33.60 billion, a PE ratio of -106.07 and a beta of 1.62. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The firm’s 50 day simple moving average is $233.44 and its two-hundred day simple moving average is $190.60.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s revenue was up 34.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) EPS. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Vanguard Group Inc. increased its holdings in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares during the period. State Street Corp boosted its position in Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the last quarter. Franklin Resources Inc. increased its holdings in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares during the period. Finally, Geode Capital Management LLC raised its position in Natera by 7.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after buying an additional 166,768 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several analyst reports. TD Cowen reissued a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Stephens upped their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Barclays raised their price objective on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. boosted their target price on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.